PATIENT-REPORTED WELL-BEING USING TILDRAKIZUMAB IN A REAL-WORLD SETTING: 52WEEK INTERIM DATA OF THE PHASE IV POSITIVE STUDY

被引：0

作者：

Sommer, Rachel ^{[1
]}

Augustin, Matthias ^{[1
]}

Reguiai, Ziad ^{[2
]}

Gerdes, Sascha ^{[3
]}

Dauden, Esteban ^{[4
]}

Weger, Wolfgang ^{[5
]}

Maul, Julia-Tatjana ^{[6
,7
]}

Laws, Philip ^{[8
]}

Naldi, Luigi ^{[9
]}

Ghislain, Pierre-Dominique ^{[10
]}

Jong, Elke de ^{[11
]}

Mburu, Sicily ^{[12
]}

Koscielny, Volker ^{[13
]}

Massana, Eric ^{[13
]}

Kasujee, Ismail ^{[13
]}

Mrowietz, Ulrich ^{[14
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany

[2] Polyclin Courlancy Bezannes, Dermatol Dept, Reims, France

[3] Univ Med Ctr Schleswig Holstein, Ctr Inflammatory Skin Dis, Dept Dermatol Venereol & Allergol, Campus Kiel, Kiel, Germany

[4] La Princesa Univ Hosp, Inst Invest Sanitaria La Princesa IIS IP, Madrid, Spain

[5] Med Univ Graz, Dept Dermatol & Venereol, Graz, Austria

[6] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland

[7] Univ Zurich, Fac Med, Zurich, Switzerland

[8] Leeds Teaching Hosp NHS Trust, Leeds, England

[9] San Bortolo Hosp, Div Dermatol, Vicenza, Italy

[10] Catholic Univ Louvain, Clin Univ St Luc, Dept Dermatol, Brussels, Belgium

[11] Radboud Univ Med Ctr Radboudumc, Dept Dermatol, Nijmegen, Netherlands

[12] Int Federat Psoriasis Assoc, Stockholm, Sweden

[13] Almirall GMA, Barcelona, Spain

[14] Univ Med Ctr Schleswig Holstein, Psoriasis Ctr, Dept Dermatol, Campus Kiel, Kiel, Germany

来源：

ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P-045

引用

页数：102

共 50 条

[1] Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study
Weger, W.
Gruber, B.
Ratzinger, G.
Sator, P-G
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S352 - S352
[2] IMPACT OF PATIENT PSORIASIS ON PARTNER WELL-BEING IN A REAL-WORLD SETTING: 52-WEEK INTERIM DATA OF THE PHASE IV POSITIVE STUDY
Mrowietz, Ulrich
Sommer, Rachel
Reguiai, Ziad
Gerdes, Sascha
Dauden, Esteban
Weger, Wolfgang
Maul, Julia-Tatjana
Laws, Philip
Naldi, Luigi
Ghislain, Pierre-Dominique
de Jong, Elke
Mburu, Sicily
Koscielny, Volker
Massana, Eric
Kasujee, Ismail
Augustin, Matthias
[J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
[3] Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)
Augustin, Matthias
Sommer, Rachel
Dauden, Esteban
Laws, Philip
de Jong, Elke
Fabbrocini, Gabriella
Naldi, Luigi
Navarini, Alexander
Lambert, Jo
Reguiai, Ziad
Gerdes, Sascha
Massana, Eric
Obis, Teresa
Kasujee, Ismail
Mrowietz, Ulrich
[J]. BMJ OPEN, 2023, 13 (02):
[4] EFFECTIVENESS AND PATIENT-REPORTED WELLBEING OF TILDRAKIZUMAB IN PATIENTS WITH NAIL PSORIASIS: 52-WEEK RESULTS FROM THE PHASE IV POSITIVE STUDY
Weger, Wolfgang
Gruber, Barbara
Ratzinger, Gudrun
Sator, Paul-Gunther
[J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
[5] Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis
Bhatia, Neal
Heim, Jayme
Schenkel, Brad
Vasquez, J. Gabriel
[J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
[6] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
Augustin, Matthias
Sommer, Raquel
Reguiai, Ziad
Gerdes, Sascha
Dauden, Esteban
Weger, Wolfgang
Maul, Julia-Tatjana
Laws, Philip
Naldi, Luigi
Ghislain, Pierre-Dominique
de Jong, Elke
Mburu, Sicily
Koscielny, Volker
Massana, Eric
Kasujee, Ismail
Mrowietz, Ulrich
[J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
[7] A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
Heim, Jayme
Vasquez, J. Gabriel
Beute, Paulita
Torres, Monique
Rozzo, Stephen J.
Bhatia, Neal
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB132 - AB132
[8] A Phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
Heim, Jayme
Vasquez, J. Gabriel
Beute, Paulita
Torres, Monique
Rozzo, Stephen J.
Bhatia, Neal
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 6
[9] CAPTURING THE PATIENT-REPORTED IMPACT OF MYASTHENIA GRAVIS IN THE REAL-WORLD SETTING USING A SMARTPHONE APPLICATION
Assouly, Pierre
Berrih-Aknin, Sonia
Claeys, Kristl
Murai, Hiroyuki
Palace, Jacqueline
Sacca, Francesco
Baggi, Fulvio
Bagshaw, Emma
Kousoulakou, Hara
Larkin, Mark
Beauchamp, Jon
Leighton, Trevor
Paci, Sandra
[J]. MUSCLE & NERVE, 2020, 62 : S65 - S66
[10] Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a phase 4 study
Bhatia, Neal
Heim, Jayme
Torres, Monique
Beute, Paulita
Rozzo, Stephen J.
Vasquez, J. Gabriel
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB199 - AB199

← 1 2 3 4 5 →